This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ludwig, L. Articles by Schmid, R. M. Search for Related Content PubMed PubMed Citation Articles by Ludwig, L. Articles by Schmid, R. M.

Nuclear Factor-B Is Constitutively Active in C-Cell Carcinoma and Required for RET-induced Transformation¹

Department of Internal Medicine I, University of Ulm, 89081 Ulm [L. L., H. K., M. W., G. A., B. O. B., R. M. S.], and Department of Surgery I, University of Halle-Wittenberg, 06097 Halle [C. H-V., H. D.], Germany

Specific point mutations of the RET proto-oncogene have been demonstrated to be responsible for multiple endocrine neoplasia (MEN) types 2A and 2B, for familial medullary thyroid carcinoma (MTC) syndromes, as well as for sporadic MTC. Here we show that nuclear factor (NF)-B is activated in RET-associated C-cell carcinoma specimens. TT cells, a human MTC cell line expressing MEN 2A type RET, display transcriptionally active RelA(p65) in the nucleus. NF-B activity in these cells is attributable to constitutive IB kinase (IKK) activity and high turn over of IB. RET harboring the mutations C634R (MEN 2A) or M918T (MEN 2B), in contrast to wild-type RET, activates a NF-B-dependent reporter construct upon transient transfection in HeLa cells. We show that the prototype RET mutation C634R enhances phosphorylation of IB by IKKß but not by IKK. RET-induced NF-B and IKKß activity requires Ras function but does neither involve the classical mitogen-activated protein kinase kinase/extracellular signal-regulated kinase nor the phosphoinositide 3-kinase/Akt pathways. In contrast, RET-induced NF-B activity is dependent on Raf and MEKK1. Inhibition of constitutive NF-B activity results in cell death of TT cells and blocks focus formation induced by oncogenic forms of RET in NIH 3T3 cells. These results suggest that RET-mediated carcinogenesis critically depends on IKK activity and subsequent NF-B activation.

This article has been cited by other articles:

				A. Cerrato, V. De Falco, and M. Santoro Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets J. Mol. Endocrinol., October 1, 2009; 43(4): 143 - 155. [Abstract] [Full Text] [PDF]

				L. Zhang, S. Altuwaijri, F. Deng, L. Chen, P. Lal, U. K. Bhanot, R. Korets, S. Wenske, H. G. Lilja, C. Chang, et al. NF-{kappa}B Regulates Androgen Receptor Expression and Prostate Cancer Growth Am. J. Pathol., August 1, 2009; 175(2): 489 - 499. [Abstract] [Full Text] [PDF]

				J. S. Pufnock and J. L. Rothstein Oncoprotein Signaling Mediates Tumor-Specific Inflammation and Enhances Tumor Progression J. Immunol., May 1, 2009; 182(9): 5498 - 5506. [Abstract] [Full Text] [PDF]

				D. Hong, L. Ye, R. Gagel, L. Chintala, A. K. El Naggar, J. Wright, and R. Kurzrock Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib Mol. Cancer Ther., May 1, 2008; 7(5): 1001 - 1006. [Abstract] [Full Text] [PDF]

				G. Sethi, B. Sung, and B. B. Aggarwal Nuclear Factor-{kappa}B Activation: From Bench to Bedside Experimental Biology and Medicine, January 1, 2008; 233(1): 21 - 31. [Abstract] [Full Text] [PDF]

				G. Riesco-Eizaguirre and P. Santisteban New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy Endocr. Relat. Cancer, December 1, 2007; 14(4): 957 - 977. [Abstract] [Full Text] [PDF]

				S. Ruiz-Llorente, C. Montero-Conde, R. L. Milne, C. M. Moya, A. Cebrian, R. Leton, A. Cascon, F. Mercadillo, I. Landa, S. Borrego, et al. Association Study of 69 Genes in the Ret Pathway Identifies Low-penetrance Loci in Sporadic Medullary Thyroid Carcinoma Cancer Res., October 1, 2007; 67(19): 9561 - 9567. [Abstract] [Full Text] [PDF]

				H.-Q. Wang, Z.-X. Du, H.-Y. Zhang, and D.-X. Gao Different Induction of GRP78 and CHOP as a Predictor of Sensitivity to Proteasome Inhibitors in Thyroid Cancer Cells Endocrinology, July 1, 2007; 148(7): 3258 - 3270. [Abstract] [Full Text] [PDF]

				C. S. Mitsiades, D. McMillin, V. Kotoula, V. Poulaki, C. McMullan, J. Negri, G. Fanourakis, S. Tseleni-Balafouta, K. B. Ain, and N. Mitsiades Antitumor Effects of the Proteasome Inhibitor Bortezomib in Medullary and Anaplastic Thyroid Carcinoma Cells in Vitro J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 4013 - 4021. [Abstract] [Full Text] [PDF]

				C. J. Strock, J.-I. Park, D. M. Rosen, B. Ruggeri, S. R. Denmeade, D. W. Ball, and B. D. Nelkin Activity of Irinotecan and the Tyrosine Kinase Inhibitor CEP-751 in Medullary Thyroid Cancer J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 79 - 84. [Abstract] [Full Text] [PDF]

				S Corbetta, L Vicentini, S Ferrero, A Lania, G Mantovani, D Cordella, P Beck-Peccoz, and A Spada Activity and function of the nuclear factor kappaB pathway in human parathyroid tumors Endocr. Relat. Cancer, December 1, 2005; 12(4): 929 - 937. [Abstract] [Full Text] [PDF]

				U. Haussler, G. von Wichert, R. M. Schmid, F. Keller, and G. Schneider Epidermal growth factor activates nuclear factor-{kappa}B in human proximal tubule cells Am J Physiol Renal Physiol, October 1, 2005; 289(4): F808 - F815. [Abstract] [Full Text] [PDF]

				E Puxeddu, J A Knauf, M A Sartor, N Mitsutake, E P Smith, M Medvedovic, C R Tomlinson, S Moretti, and J A Fagin RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response Endocr. Relat. Cancer, June 1, 2005; 12(2): 319 - 334. [Abstract] [Full Text] [PDF]

				F. Pacifico, C. Mauro, C. Barone, E. Crescenzi, S. Mellone, M. Monaco, G. Chiappetta, G. Terrazzano, D. Liguoro, P. Vito, et al. Oncogenic and Anti-apoptotic Activity of NF-{kappa}B in Human Thyroid Carcinomas J. Biol. Chem., December 24, 2004; 279(52): 54610 - 54619. [Abstract] [Full Text] [PDF]

				V. Quidville, N. Segond, E. Pidoux, R. Cohen, A. Jullienne, and S. Lausson Tumor Growth Inhibition by Indomethacin in a Mouse Model of Human Medullary Thyroid Cancer: Implication of Cyclooxygenases and 15-Hydroxyprostaglandin Dehydrogenase Endocrinology, May 1, 2004; 145(5): 2561 - 2571. [Abstract] [Full Text] [PDF]

				D. Starenki, H. Namba, V. Saenko, A. Ohtsuru, and S. Yamashita Inhibition of Nuclear Factor-{kappa}B Cascade Potentiates the Effect of a Combination Treatment of Anaplastic Thyroid Cancer Cells J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 410 - 418. [Abstract] [Full Text] [PDF]

				Y. Cohen, M. Xing, E. Mambo, Z. Guo, G. Wu, B. Trink, U. Beller, W. H. Westra, P. W. Ladenson, and D. Sidransky BRAF Mutation in Papillary Thyroid Carcinoma J Natl Cancer Inst, April 16, 2003; 95(8): 625 - 627. [Abstract] [Full Text] [PDF]

				B. Rayet, Y. Fan, and C. Gelinas Mutations in the v-Rel Transactivation Domain Indicate Altered Phosphorylation and Identify a Subset of NF-{kappa}B-Regulated Cell Death Inhibitors Important for v-Rel Transforming Activity Mol. Cell. Biol., March 1, 2003; 23(5): 1520 - 1533. [Abstract] [Full Text] [PDF]

				G. Munzert, D. Kirchner, H. Stobbe, L. Bergmann, R. M. Schmid, H. Dohner, and H. Heimpel Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis Blood, November 15, 2002; 100(10): 3749 - 3756. [Abstract] [Full Text] [PDF]

				A. Arlt, J. Vorndamm, S. Muerkoster, H. Yu, W. E. Schmidt, U. R. Folsch, and H. Schafer Autocrine Production of Interleukin 1{beta} Confers Constitutive Nuclear Factor {kappa}B Activity and Chemoresistance in Pancreatic Carcinoma Cell Lines Cancer Res., February 1, 2002; 62(3): 910 - 916. [Abstract] [Full Text] [PDF]